News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Medicsight (MSHT.OB) Announces New Global Marketing Partnership with Ziosoft Unveiled at RSNA 2008


11/25/2008 9:51:04 AM

NEW YORK, Nov. 25 /PRNewswire/ -- Medicsight PLC, a subsidiary of MGT Capital Investments, Inc. , and an industry leader in the development of Computer-Aided Detection (CAD) and image analysis software, today announced a new global partnership with Ziosoft Inc ("Ziosoft"), a leading developer of 3D advanced visualization and analysis technology. Combined Ziosoft-Medicsight products for the detection of colorectal polyps will be distributed through the Ziosoft network.

Both companies are presenting at the 94th Scientific Assembly and Annual Meeting of the Radiological Society of North America, which is being held in Chicago, 30 November until 5 December 2008. The companies are demonstrating the first results of the partnership at the Ziosoft booth (#7957).

Ziosoft is a market leader for 3D workstations. In 2007 the company had an install base of more than 1,500 3D systems. The companies are working together to integrate Medicsight's ColonCAD(TM) with Ziosoft's Ziostation, and the product is due for global launch early in 2009. U.S. launch will follow the product's clearance by the U.S. Food and Drug Administration, also expected in early 2009.

David Sumner, Chief Executive of Medicsight, said: "The partnership with Ziosoft is part of our ongoing strategy to build a broad base distribution channel, which will enable us to quickly penetrate global markets. Global demand for CT colonography looks set to increase dramatically, with clinical evidence such as the recently published U.S. National CT Colonography Trial (ACRIN 6664) demonstrating the positive benefits of CTC as a screening procedure for the early detection of colorectal cancer."

"This is the ideal time for Ziosoft to partner with Medicsight," said Mark Koeniguer, COO of Ziosoft. "There is great demand from the radiology community for intelligent software that will increase their productivity. The partnership will enable us to combine our revolutionary 3D imaging applications with the CAD and image analysis solutions of Medicsight to fulfill our Company's goal, which is to meet the needs of any hospital."

About MGT Capital Investments, Inc.

MGT Capital Investments, Inc is a technology holding company that focuses on investments in the global healthcare information technology market. The Company has two subsidiaries, Medicsight PLC and Medicexchange PLC.

Medicsight PLC (AIM: MDST) is a UK-headquartered, research driven, leading developer of computer-aided detection (CAD) and image analysis software for the medical imaging market. The CAD software automatically highlights suspicious areas on computerized tomography (CT) scans of the colon and lung, helping radiologists to identify, measure and analyze potential disease and early indicators of disease. Medicsight's CAD software has been validated using one of the world's largest and most population diverse databases of verified patient CT scan data. Medicsight's ColonCAD(TM) and LungCAD(TM) software products are seamlessly integrated with the advanced 3D visualisation workstations of several industry-leading imaging equipment partners.

Medicexchange PLC provides medical imaging professionals with a global web portal containing an online sales, jobs and information channel for diagnostic, treatment and surgery planning solutions. This combined with a variety of relevant clinical papers, training materials and content gives these professionals access to information and products that they otherwise would have difficulty accessing.

Additional information can be found at www.mgtci.com.

All forward-looking statements are made pursuant to the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on current management expectations that involve risks and uncertainties that may result in such expectations not being realized. Potential risks and uncertainties include, but are not limited to, the risks described in company filings with the Securities and Exchange Commission.

CONTACT: Todd Fromer, +1-212-896-1215, tfromer@kcsa.com or Garth Russell,
+1-212-896-1250, grussell@kcsa.com, both of KCSA Strategic Communications

Web site: http://www.mgtci.com/


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES